SXTCHealthcare · Drug Manufacturers - Specialty & GenericTicker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 7 of 100 as at 31 Oct 2026 — in the weakest quartile.
Consensus tells you what everyone already believes. The model scores China Sxt Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (98): Smaller than most of the companies we track.
Value (5): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on SXTC, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
SXTC appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 74% of US stocks
Cheaper than 88% of US stocks
Cheaper than 92% of US stocks
Cheaper than 55% of US stocks
Higher than 6% of US stocks
Higher than 12% of US stocks
Higher than 84% of US stocks
Higher than 28% of US stocks
Higher than 22% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
China Sxt Pharmaceuticals, Inc. has a market value of $326K and an enterprise value of −$25.8M.
Trailing P/E: 0.0×.
Forward dividend yield: 0.00%, paying out 0% of earnings.
China Sxt Pharmaceuticals, Inc. employs 56 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own China Sxt Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
China SXT Pharmaceuticals announced a 1-for-100 consolidation of its Class A ordinary shares, effective October 26, 2026. The shares are expected to begin trading on a post-consolidation basis at the market open that day.
Why it matters — SXTC watchers may wish to note the consolidation ratio and the date the shares are expected to trade on a post-consolidation basis.
China SXT Pharmaceuticals entered into a termination letter agreement with the purchasers in its October 8 registered direct offering, terminating in full the additional purchase right in the related securities purchase agreement.
Why it matters — The agreement changes a term associated with the offering, which SXTC watchers may track as part of the company’s financing activity.
China SXT Pharmaceuticals entered into a definitive agreement with institutional investors for a registered direct offering of 8 million Class A ordinary shares, or pre-funded warrants in lieu, at $1.50 per share. It also agreed to issue the investors 8 million warrants with an exercise price of $1.50 per share.
Why it matters — The offering terms describe a planned share issuance and warrants, which are relevant to SXTC investors tracking the company’s financing activity.
China SXT Pharmaceuticals, Inc. announced a 1-for-80 share consolidation of its Class A and Class B ordinary shares, effective August 10, 2026, with post-consolidation trading beginning that day.
Why it matters — A share consolidation reduces the number of outstanding shares and typically increases the per-share price, which can affect the stock's trading characteristics and compliance with exchange listing requirements.
Univest Securities, LLC announced the closing of a registered direct offering worth approximately $9 million for its client China SXT Pharmaceuticals Inc. (NASDAQ: SXTC), described as a China-based innovative pharmaceutical company focused on traditional Chinese medicine pieces.
Why it matters — The completion of this $9 million offering indicates SXTC has secured additional capital through a registered direct placement, which may impact the company's financial position.
As at 31 Oct 2026, China Sxt Pharmaceuticals, Inc. ranks 7 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (98 of 100).
No analyst covering China Sxt Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SXTC are extrapolating price history, which says nothing about the business.
China SXT Pharmaceuticals, Inc. is a pharmaceutical company focused on the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces.
The most recent item we track (PRNewsWire, 22 Oct 2026): "China SXT Pharmaceuticals, Inc. Announces Share Consolidation". China SXT Pharmaceuticals announced a 1-for-100 consolidation of its Class A ordinary shares, effective October 26, 2026. The shares are expected to begin trading on a post-consolidation basis at the market open that day.
China SXT Pharmaceuticals, Inc. is a pharmaceutical company focused on the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces. Its product lineup includes directly-oral, after-soaking-oral, fine, and regular TCMP formats, which are distributed under brands such as Suxuantang, Hui Chun Tang, and Tong Ren Tang. The company serves a range of customers in China, including hospitals, chain pharmacies, pharmaceutical distributors, and commercial pharmaceutical companies, positioning it within the domestic traditional medicine supply chain. Based in Taizhou, Jiangsu, China, China SXT Pharmaceuticals, Inc. operates in a specialized segment of the healthcare market centered on traditional Chinese medicine products.
CEO Mr. Feng Zhou · 56 employees · China · https://www.sxtchina.com